Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new
and updated data from its oncology and hematology pipeline will be
shared across 17 presentations at the American Society of Clinical
Oncology (ASCO) 2024 Annual Meeting, taking place from May 31 to
June 5 in Chicago, IL. Notably, new safety and efficacy results
from a Phase 1/2 trial investigating the costimulatory bispecific
antibody REGN7075 (EGFRxCD28) in combination with Libtayo in
patients with certain advanced solid tumors will be featured in an
oral presentation.
“The breadth of our presentations at ASCO showcase our progress
in advancing multiple promising and distinct investigational
treatment approaches for a diverse array of difficult-to-treat
cancers,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair,
President and Chief Scientific Officer at Regeneron. “These latest
clinical results build on our ongoing commitment to cancer research
and reflect our focus on advancing a pipeline of
internally-developed candidates that have the potential to offer
novel and differentiated therapies. Poised to tackle more than 30
types of cancer, our oncology pipeline is a testament to
Regeneron’s relentless commitment to transforming cancer care for
those who need it most.”
Beyond the REGN7075 data, additional presentations will feature
results from Regeneron’s diverse pipeline of checkpoint inhibitors
and bispecific antibodies. Among them are presentations on updated
data and new analyses for linvoseltamab (BCMAxCD3) in multiple
myeloma; odronextamab (CD20xCD3) in several lymphoma subtypes;
REGN6569 (GITR) in combination with Libtayo across solid tumors;
and fianlimab (LAG-3 inhibitor) in combination with Libtayo in
non-small cell lung cancer, melanoma and head and neck cancer.
Regeneron presentations at ASCO:
Medicine |
Abstract title |
Abstract |
Lead author |
Presentation date/time (all
CDT) |
Solid Tumor Malignancies |
REGN7075, Libtayo |
A Phase 1/2 study of REGN7075 in combination with cemiplimab in
patients with advanced solid tumors: Updated dose escalation
results |
#2503 Oral Presentation Session— Developmental
Therapeutics—Immunotherapy |
Segal, N.H. |
Monday, June3 11:30 a.m. –2:30 p.m. |
REGN6569, Libtayo |
A Phase 1 study of REGN6569, a GITR mAb, in combination with
cemiplimab in patients (pts) with advanced solid tumor
malignancies: Initial dose-escalation results |
#2650 Poster Presentation Session— Developmental
Therapeutics—Immunotherapy |
Lakhani, N.J. |
Saturday, June1 9:00 a.m. –12:00 p.m. |
Blood Cancer |
Linvoseltamab |
Indirect comparison of linvoseltamab (linvo) versus teclistamab
(tec) for treatment of triple-class exposed (TCE)
relapsed/refractory multiple myeloma (RRMM) |
#7560 Poster Presentation Session— Hematologic
Malignancies—Plasma Cell
Dyscrasia |
Jagannath, S. |
Monday, June3 9:00 a.m. –12:00 p.m. |
Linvoseltamab |
Comparative effectiveness of linvoseltamab (Linvo) vs. standard of
care (SOC) in real-world patients (pts) with triple class exposed
(TCE) relapsed/refractory multiple myeloma
(RRMM) |
#7561 Poster Presentation Session— Hematologic
Malignancies—Plasma Cell
Dyscrasia |
Kumar, S. |
Monday, June3 9:00 a.m. –12:00 p.m. |
Odronextamab |
Phase 3 trial evaluating the efficacy and safety of odronextamab
versus investigator’s choice in previously untreated follicular
lymphoma (OLYMPIA-1) |
#7096 Poster Presentation Session— Hematologic
Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Birhiray, R. |
Monday, June3 9:00 a.m. –12:00 p.m. |
Odronextamab |
Phase 3 trial evaluating the efficacy and safety of odronextamab
plus chemotherapy versus rituximab plus chemotherapy in previously
untreated follicular lymphoma (OLYMPIA-2) |
#7099 Poster Presentation Session— Hematologic
Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Hardin, C. |
Monday, June3 9:00 a.m. –12:00 p.m. |
Odronextamab |
Phase 3 trial evaluating efficacy and safety of odronextamab plus
CHOP vs rituximab plus CHOP in previously untreated diffuse large
B-cell lymphoma (DLBCL; OLYMPIA-3) |
#7086Poster Presentation Session— Hematologic
Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Matasar, M. |
Monday, June3 9:00 a.m. –12:00 p.m. |
Odronextamab |
Phase 3 trial evaluating the efficacy and safety of odronextamab
versus standard-of-care (SOC) therapy in relapsed/refractory (R/R)
aggressive B-cell non-Hodgkin lymphoma (B-NHL;OLYMPIA-4) |
#7093 Poster Presentation Session— Hematologic
Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Hawkes, E.A. |
Monday, June3 9:00 a.m. –12:00 p.m. |
Odronextamab |
Phase 3 trial of odronextamab plus lenalidomide versus rituximab
plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma
(FL) and marginal one lymphoma (MZL; (OLYMPIA-5) |
#7094 Poster Presentation Session— Hematologic
Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Vitolo, U. |
Monday, June3 9:00 a.m. –12:00 p.m. |
Odronextamab |
Results from the follicular lymphoma (FL) outcomes in
relapsed/refractory (R/R) patients treated with systemic therapy in
a real-world assessment (FLORA) study |
#7076 Poster Presentation Session— Hematologic
Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Luminari, S. |
Monday, June3 9:00 a.m. –12:00 p.m. |
Skin Cancer |
Fianlimab, Libtayo |
A Phase 3 trial of fixed dose combinations of fianlimab
(anti-LAG-3) + cemiplimab (anti-PD-1) versus relatlimab + nivolumab
in patients with unresectable or metastatic melanoma |
#TPS9611 Poster Presentation Session— Melanoma/Skin
Cancers |
Khushalani, N.I. |
Saturday, June1 1:30 p.m. –4:30 p.m. |
Lung Cancer |
Fianlimab,Libtayo |
A Phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy
versus cemiplimab plus chemotherapy in first-line advanced
non-small cell lung cancer |
#TPS8660 Poster Presentation Session— Lung
Cancer—Non-Small Cell Metastatic |
Gabrail, N. |
Monday, June3 1:30 p.m. –4:30 p.m |
Fianlimab, Libtayo |
A Phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in
patients with advanced non-small cell lung cancer with tumors
expressing PD-L ≥50% |
#TPS8663 Poster Presentation Session— Lung
Cancer—Non-Small Cell Metastatic |
Faulkner, N. |
Monday, June3 1:30 p.m. –4:30 p.m. |
Gynecologic Cancer |
Libtayo |
Combination of cemiplimab and ISA101b vaccine for the treatment of
recurrent/metastatic HPV16 cervical cancer* |
#5522 Poster Presentation Session— Gynecologic
Cancer |
Lorusso, D. |
Monday, June3 9:00 a.m. –12:00 p.m. |
Ubamatamab, Libtayo |
A Phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific
antibody, administered alone or in combination with cemiplimab
(anti–PD-1) in patients with recurrent ovarian cancer or MUC16+
endometrial cancer: Trial in progress update |
#TPS5632 Poster Presentation Session— Gynecologic
Cancer |
Nieuwenhuysen, E. |
Monday, June3 9:00 a.m. – 12:00 p.m. |
Head and Neck Cancer |
Fianlimab,Libtayo |
A Phase 1 study of fianlimab (anti-LAG-3) in combination with
cemiplimab (anti-PD-1) in patients with advanced HNSCC |
#6038 Poster Presentation Session— Head and Neck
Cancer |
Cho, B.C. |
Sunday, June2 9:00 a.m. –12:00 p.m. |
DB-020 |
A phase 1 clinical trial of DB-020 intratympanic injections
administered prior to high dose cisplatin chemotherapy to reduce
ototoxicity |
#6100Poster Presentation Session— Head and Neck
Cancer |
Rischin, D. |
Sunday, June2 9:00 a.m. – 12:00 p.m. |
*Study conducted in collaboration between Regeneron and ISA.
The potential uses of Libtayo, REGN7075, odronextamab,
linvoseltamab, REGN6569, fianlimab and DB-020 as described above
are investigational, and their safety and efficacy in these uses
have not been fully evaluated by any regulatory authority.
REGN7075, odronextamab, linvoseltamab, REGN6569, fianlimab and
DB-020 are not currently approved for use in any
indication.
About Regeneron in Cancer We aspire to
turn revolutionary discoveries into medicines that can transform
the lives of those impacted by cancer. Our team around the world is
driven to solve the needs and challenges of those affected by one
of the most serious diseases of our time.
Backed by our legacy of scientific innovation and a deep
understanding of biology, genetics and the immune system, we’re
pursuing potential therapies across more than 30 types of solid
tumors and blood cancers. Our cancer strategy is powered by
cutting-edge technologies and therapies that can be flexibly
combined to investigate potentially transformative treatments for
patients. Oncology assets in clinical development comprise nearly
half of Regeneron’s pipeline, and include checkpoint inhibitors,
bispecific antibodies and costimulatory bispecific antibodies. Our
approved PD-1 inhibitor Libtayo serves as the backbone of many of
our investigational combinations.
To complement our extensive in-house capabilities, we
collaborate with patients, healthcare providers, governments,
biopharma companies and each other to further our shared goals.
Together, we are united in the mission to serve as a beacon of
transformation in cancer care.
About Libtayo Libtayo is a fully
human monoclonal antibody targeting the immune checkpoint receptor
PD-1 on T cells and was invented using Regeneron's proprietary
VelocImmune® technology. By binding to PD-1, Libtayo has been shown
to block cancer cells from using the PD-1 pathway to suppress
T-cell activation. In the U.S. and other countries
Libtayo is indicated in certain patients with advanced basal cell
carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC)
and advanced non-small cell lung cancer (NSCLC), as well as in
advanced cervical cancer in the European Union, Canada
and Brazil. As of July 1, 2022, Libtayo is developed and
marketed globally by Regeneron.
In the U.S., the generic name for Libtayo in its
approved indications is cemiplimab-rwlc, with rwlc as the suffix
designated in accordance with Nonproprietary Naming of Biological
Products Guidance for Industry issued by the U.S. Food and Drug
Administration (FDA). Outside of the U.S., the generic name of
Libtayo in its approved indication is cemiplimab.
The extensive clinical program for Libtayo is focused on
difficult-to-treat cancers. Libtayo is currently being investigated
in trials as a monotherapy, as well as in combination with either
conventional or novel therapeutic approaches for other solid tumors
and blood cancers. These potential uses are investigational, and
their safety and efficacy have not been evaluated by any regulatory
authority.
U.S. FDA-approved
Indications Libtayo is a prescription
medicine used to treat:
- People with a type of skin cancer called cutaneous squamous
cell carcinoma (CSCC) that has spread or cannot be cured by surgery
or radiation.
- People with a type of skin cancer called basal cell carcinoma
(BCC) when your BCC cannot be removed by surgery (locally advanced
BCC) or when it has spread (metastatic BCC) and have received
treatment with a hedgehog pathway inhibitor (HHI), or cannot
receive treatment with a HHI.
- Adults with a type of lung cancer called non-small cell lung
cancer (NSCLC).
- LIBTAYO may be used in combination with chemotherapy that
contains a platinum medicine as your first treatment when your lung
cancer has not spread outside your chest (locally advanced lung
cancer) and you cannot have surgery or chemotherapy with radiation,
or your lung cancer has spread to other areas of your body
(metastatic lung cancer), and your tumor does not have an abnormal
“EGFR,” “ALK,” or “ROS1” gene.
- LIBTAYO may be used alone as your first treatment when your
lung cancer has not spread outside your chest (locally advanced
lung cancer) and you cannot have surgery or chemotherapy with
radiation, or your lung cancer has spread to other areas of your
body (metastatic lung cancer), and your tumor tests positive for
high “PD-L1,” and your tumor does not have an abnormal “EGFR,”
“ALK,” or “ROS1” gene.
It is not known if Libtayo is safe and effective in
children. IMPORTANT SAFETY INFORMATION
FOR U.S. PATIENTS What is the most
important information I should know about
LIBTAYO? LIBTAYO is a medicine that may treat
certain cancers by working with your immune system. LIBTAYO can
cause your immune system to attack normal organs and tissues in any
area of your body and can affect the way they work. These problems
can sometimes become severe or life-threatening and can lead to
death. You can have more than one of these problems at the same
time. These problems may happen anytime during treatment or even
after your treatment has ended. Call or see
your healthcare provider right away if you develop any new or
worsening signs or symptoms, including:
- Lung problems: cough, shortness of breath, or
chest pain
- Intestinal problems: diarrhea (loose stools)
or more frequent bowel movements than usual, stools that are black,
tarry, sticky or have blood or mucus, or severe stomach-area
(abdomen) pain or tenderness
- Liver problems: yellowing of your skin or the
whites of your eyes, severe nausea or vomiting, pain on the right
side of your stomach-area (abdomen), dark urine (tea colored), or
bleeding or bruising more easily than normal
- Hormone gland problems: headache that will not
go away or unusual headaches, eye sensitivity to light, eye
problems, rapid heartbeat, increased sweating, extreme tiredness,
weight gain or weight loss, feeling more hungry or thirsty than
usual, urinating more often than usual, hair loss, feeling cold,
constipation, your voice gets deeper, dizziness or fainting, or
changes in mood or behavior, such as decreased sex drive,
irritability, or forgetfulness
- Kidney problems: decrease in your amount of
urine, blood in your urine, swelling of your ankles, or loss of
appetite
- Skin problems: rash, itching, skin blistering
or peeling, painful sores or ulcers in mouth or nose, throat, or
genital area, fever or flu-like symptoms, or swollen lymph
nodes
- Problems can also happen in other organs and tissues.
These are not all of the signs and symptoms of immune system
problems that can happen with LIBTAYO. Call or see your healthcare
provider right away for any new or worsening signs or symptoms,
which may include: chest pain, irregular heartbeat,
shortness of breath or swelling of ankles, confusion, sleepiness,
memory problems, changes in mood or behavior, stiff neck, balance
problems, tingling or numbness of the arms or legs, double vision,
blurry vision, sensitivity to light, eye pain, changes in eyesight,
persistent or severe muscle pain or weakness, muscle cramps, low
red blood cells, or bruising
- Infusion reactions that can sometimes be severe or
life-threatening. Signs and symptoms of infusion reactions
may include: nausea, vomiting, chills or shaking, itching or rash,
flushing, shortness of breath or wheezing, dizziness, feel like
passing out, fever, back or neck pain, or facial
swelling
- Rejection of a transplanted organ. Your
healthcare provider should tell you what signs and symptoms you
should report and monitor you, depending on the type of organ
transplant that you have had
- Complications, including graft-versus-host disease
(GVHD), in people who have received a bone marrow (stem cell)
transplant that uses donor stem cells (allogeneic). These
complications can be serious and can lead to death. These
complications may happen if you underwent transplantation either
before or after being treated with LIBTAYO. Your healthcare
provider will monitor you for these complications
Getting medical treatment right away may help keep these
problems from becoming more serious. Your healthcare
provider will check you for these problems during your treatment
with LIBTAYO. Your healthcare provider may treat you with
corticosteroid or hormone replacement medicines. Your healthcare
provider may also need to delay or completely stop treatment with
LIBTAYO if you have severe side
effects. Before you receive LIBTAYO, tell your
healthcare provider about all your medical conditions, including if
you:
- have immune system problems such as Crohn’s disease, ulcerative
colitis, or lupus
- have received an organ transplant
- have received or plan to receive a stem cell transplant that
uses donor stem cells (allogeneic)
- have received radiation treatment to your chest
area
- have a condition that affects your nervous system, such as
myasthenia gravis or Guillain-Barré syndrome
- are pregnant or plan to become pregnant. LIBTAYO can harm your
unborn baby
- are breastfeeding or plan to breastfeed. It is not known if
LIBTAYO passes into your breast milk. Do not breastfeed during
treatment and for at least 4 months after the last dose of
LIBTAYOFemales who are able to become
pregnant:
- Your healthcare provider will give you a pregnancy test before
you start treatment
- You should use an effective method of birth control during your
treatment and for at least 4 months after your last dose of
LIBTAYO. Talk to your healthcare provider about birth control
methods that you can use during this time
- Tell your healthcare provider right away if you become pregnant
or think you may be pregnant during treatment with
LIBTAYO
Tell your healthcare provider about all the medicines
you take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. The most
common side effects of LIBTAYO when used alone include tiredness,
muscle or bone pain, rash, diarrhea, and low levels of red blood
cells (anemia). The most common side effects of LIBTAYO when used
in combination with platinum-containing chemotherapy include hair
loss, muscle or bone pain, nausea, tiredness, numbness, pain,
tingling, or burning in your hands or feet, and decreased appetite.
These are not all the possible side effects of LIBTAYO. Call your
doctor for medical advice about side effects. You may report side
effects to FDA at 1-800-FDA-1088. You may also report side effects
to Regeneron Pharmaceuticals at
1-877-542-8296. Please see
full Prescribing Information,
including Medication
Guide. About
Regeneron's VelocImmune Technology Regeneron's VelocImmune technology
utilizes a proprietary genetically engineered mouse platform
endowed with a genetically humanized immune system to produce
optimized fully human antibodies. When Regeneron's co-Founder,
President and Chief Scientific Officer George D.
Yancopoulos was a graduate student with his
mentor Frederick W. Alt in 1985, they were the first
to envision making such a genetically humanized mouse,
and Regeneron has spent decades inventing and developing
VelocImmune and
related VelociSuite® technologies. Dr.
Yancopoulos and his team have
used VelocImmune technology to create a substantial
proportion of all original, FDA-approved or authorized fully human
monoclonal antibodies. This includes REGEN-COV® (casirivimab
and imdevimab), Dupixent® (dupilumab), Libtayo®,
Praluent® (alirocumab), Kevzara® (sarilumab),
Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab,
maftivimab and odesivimab-ebgn) and Veopoz®
(pozelimab-bbfg).
About Regeneron Regeneron is a leading
biotechnology company that invents, develops, and commercializes
life-transforming medicines for people with serious diseases.
Founded and led for 35 years by physician-scientists, Regeneron's
unique ability to repeatedly and consistently translate science
into medicine has led to numerous FDA-approved treatments and
product candidates in development, almost all of which were
homegrown in Regeneron's laboratories. Regeneron's medicines and
pipeline are designed to help patients with eye diseases, allergic
and inflammatory diseases, cancer, cardiovascular and metabolic
diseases, hematologic conditions, infectious diseases, and rare
diseases.
Regeneron is accelerating and improving the traditional drug
development process through its
proprietary VelociSuite® technologies, such as VelocImmune®, which
uses unique genetically humanized mice to produce optimized fully
human antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center®, which
is conducting one of the largest genetics sequencing efforts in the
world.
For additional information about Regeneron, please
visit www.regeneron.com or follow Regeneron on LinkedIn.
Forward-Looking Statements and Use of Digital
Media This press release includes forward-looking
statements that involve risks and uncertainties relating to future
events and the future performance of Regeneron
Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and
actual events or results may differ materially from these
forward-looking statements. Words such as “anticipate,” “expect,”
“intend,” “plan,” “believe,” “seek,” “estimate,” variations of such
words, and similar expressions are intended to identify such
forward-looking statements, although not all forward-looking
statements contain these identifying words. These statements
concern, and these risks and uncertainties include, among others,
the nature, timing, and possible success and therapeutic
applications of products marketed or otherwise commercialized by
Regeneron and/or its collaborators or licensees (collectively,
“Regeneron’s Products”) and product candidates being developed by
Regeneron and/or its collaborators or licensees (collectively,
“Regeneron’s Product Candidates”) and research and clinical
programs now underway or planned, including without limitation
REGN7075 in combination with Libtayo® (cemiplimab), odronextamab,
linvoseltamab, fianlimab in combination with Libtayo, and other of
Regeneron’s Product Candidates discussed or referenced in this
press release; the likelihood, timing, and scope of possible
regulatory approval and commercial launch of Regeneron’s Product
Candidates and new indications for Regeneron’s Products, such as
REGN7075 in combination with Libtayo in patients with advanced
solid tumors, odronextamab in several lymphoma subtypes,
linvoseltamab in multiple myeloma, fianlimab in combination with
Libtayo in non-small cell lung cancer, melanoma, and head and neck
cancer, and the other clinical programs discussed or referenced in
the press release; uncertainty of the utilization, market
acceptance, and commercial success of Regeneron’s Products and
Regeneron’s Product Candidates and the impact of studies (whether
conducted by Regeneron or others and whether mandated or
voluntary), including the studies discussed or referenced in this
press release, on any of the foregoing or any potential regulatory
approval of Regeneron’s Products and Regeneron’s Product Candidates
(such as those referenced above); the ability of Regeneron’s
collaborators, licensees, suppliers, or other third parties (as
applicable) to perform manufacturing, filling, finishing,
packaging, labeling, distribution, and other steps related to
Regeneron’s Products and Regeneron’s Product Candidates; the
ability of Regeneron to manage supply chains for multiple products
and product candidates; safety issues resulting from the
administration of Regeneron’s Products and Regeneron’s Product
Candidates (such as those referenced above) in patients, including
serious complications or side effects in connection with the use of
Regeneron’s Products and Regeneron’s Product Candidates in clinical
trials; determinations by regulatory and administrative
governmental authorities which may delay or restrict Regeneron’s
ability to continue to develop or commercialize Regeneron’s
Products and Regeneron’s Product Candidates; ongoing regulatory
obligations and oversight impacting Regeneron’s Products, research
and clinical programs, and business, including those relating to
patient privacy; the availability and extent of reimbursement of
Regeneron’s Products from third-party payers, including private
payer healthcare and insurance programs, health maintenance
organizations, pharmacy benefit management companies, and
government programs such as Medicare and Medicaid; coverage and
reimbursement determinations by such payers and new policies and
procedures adopted by such payers; competing drugs and product
candidates that may be superior to, or more cost effective than,
Regeneron’s Products and Regeneron’s Product Candidates; the extent
to which the results from the research and development programs
conducted by Regeneron and/or its collaborators or licensees may be
replicated in other studies and/or lead to advancement of product
candidates to clinical trials, therapeutic applications, or
regulatory approval; unanticipated expenses; the costs of
developing, producing, and selling products; the ability of
Regeneron to meet any of its financial projections or guidance and
changes to the assumptions underlying those projections or
guidance; the potential for any license, collaboration, or supply
agreement, including Regeneron’s agreements with Sanofi and Bayer
(or their respective affiliated companies, as applicable), to be
cancelled or terminated; the impact of public health outbreaks,
epidemics, or pandemics (such as the COVID-19 pandemic) on
Regeneron's business; and risks associated with intellectual
property of other parties and pending or future litigation relating
thereto (including without limitation the patent litigation and
other related proceedings relating to EYLEA® (aflibercept)
Injection), other litigation and other proceedings and government
investigations relating to the Company and/or its operations, the
ultimate outcome of any such proceedings and investigations, and
the impact any of the foregoing may have on Regeneron’s business,
prospects, operating results, and financial condition. A more
complete description of these and other material risks can be found
in Regeneron’s filings with the U.S. Securities and Exchange
Commission, including its Form 10-K for the year
ended December 31, 2023. Any forward-looking statements are
made based on management’s current beliefs and judgment, and the
reader is cautioned not to rely on any forward-looking statements
made by Regeneron. Regeneron does not undertake any obligation to
update (publicly or otherwise) any forward-looking statement,
including without limitation any financial projection or guidance,
whether as a result of new information, future events, or
otherwise.
Regeneron uses its media and investor relations website and
social media outlets to publish important information about the
Company, including information that may be deemed material to
investors. Financial and other information about Regeneron is
routinely posted and is accessible on Regeneron's media and
investor relations website (https://investor.regeneron.com) and its
LinkedIn page
(https://www.linkedin.com/company/regeneron-pharmaceuticals).
Contacts:Media
RelationsTaylor SkottTel: +1
914-409-2381taylor.ramsey@regeneron.com |
Investor
RelationsVesna TosicTel: +1
914-847-5443vesna.tosic@regeneron.com |
Regeneron Pharmaceuticals (NASDAQ:REGN)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024